Updated:26 May 2017 03:31:00 PM(IST)
|Bse Corporate Announcements||Back|
|Cipla becomes sublicensing partner of the Medicines Patent Pool|
|Cipla announced that the Company has become one of the seven sublicensing partners of the Medicines Patent Pool (MPP) to augment the speed of availability of Generic HIV Medicines to developing countries.
The Medicines Patent Pool (MPP) announced seven new sub-licensing agreements for the manufacture of generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG).
MPP has forged first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; It has also extended collaborations with Aurobindo, Laurus Labs and Emcure.
To date, the MPP has signed agreements with Bristol Myers-Squibb, Gilead Sciences, F. Hoffmann-La Roche, the US National Institutes of Health and ViiV Healthcare for eight antiretrovirals (ARVs) and one medicine for an HIV opportunistic infection.